<div class="govuk-grid-row">
  <div class="govuk-grid-column-two-thirds">
    <div class="gem-c-title govuk-!-margin-top-8 govuk-!-margin-bottom-8">
    <span class="govuk-caption-xl gem-c-title__context">
      Guidance
    </span>
  <h1 class="gem-c-title__text gem-c-title__text--long">
    Guidance on licensing biosimilars, ATMPs and PMFs from 1 January 2021
  </h1>
</div>
  </div>
  
  <div class="govuk-grid-column-two-thirds">
    
  <p class="gem-c-lead-paragraph">The way you apply to licence biological products will change from 1 January 2021.</p>

  </div>
</div>

<div class="govuk-grid-row">
  <div class="metadata-logo-wrapper">
    <div class="govuk-grid-column-two-thirds metadata-column">
        <div class="app-c-publisher-metadata" lang="en">
    <div class="app-c-published-dates " lang="en">
    Published 1 September 2020
</div>

      <div class="app-c-publisher-metadata__other">
        <dl data-module="track-click">
            <dt class="app-c-publisher-metadata__term">
              From:
            </dt>
            <dd class="app-c-publisher-metadata__definition" data-module="gem-toggle">
                <span class="app-c-publisher-metadata__definition-sentence">
                  <a class="govuk-link" href="/government/organisations/medicines-and-healthcare-products-regulatory-agency">Medicines and Healthcare products Regulatory Agency</a>
                </span>
            </dd>
        </dl>
      </div>
  </div>

    </div>
    <div class="govuk-grid-column-one-third">
    </div>
  </div>
</div>



  <section class="app-c-header-notice" aria-label="notice" role="region">
    <div class="app-c-header-notice__header">
      <h2 class="app-c-header-notice__title">New rules for January 2021</h2>
    </div>

    <div class="app-c-header-notice__content">
          <p class="app-c-header-notice__text govuk-body">The UK has left the EU, and the transition period after Brexit comes to an end this year.</p>
          <p class="app-c-header-notice__text govuk-body">This page tells you what you'll need to do from 1 January 2021. It will be updated if anything changes.</p>
        <div class="app-c-header-notice__links">
            <p class="govuk-body app-c-header-notice__link-intro">
              For current information, read: 
              <a data-module="track-click" data-track-category="no_deal_notice" data-track-action="/guidance/advanced-therapy-medicinal-products-regulation-and-licensing" data-track-label="Advanced therapy medicinal products: regulation and licensing" class="app-c-header-notice__link" href="/guidance/advanced-therapy-medicinal-products-regulation-and-licensing">Advanced therapy medicinal products: regulation and licensing</a>
            </p>
        </div>

        <p class="app-c-header-notice__text govuk-body">You can also read about <a data-module="track-click" data-track-category="no_deal_notice" data-track-action="/transition" data-track-label="the transition period" class="govuk-link" href="/transition">the transition period</a>.</p>
    </div>
  </section>


<div class="govuk-grid-row">
  <div class="govuk-grid-column-two-thirds">
    

      <div id="contents" class="app-c-contents-list-with-body" data-module="sticky-element-container">
      <div class="responsive-bottom-margin">
          <nav class="gem-c-contents-list  gem-c-contents-list--no-underline " role="navigation" data-module="track-click">
      <h2 class="gem-c-contents-list__title">Contents</h2>

    <ol class="gem-c-contents-list__list">
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 1" data-track-label="#guidance-for-great-britain-england-wales-and-scotland-marketing-authorisation-applications-for-similar-biological-products-biosimilars-from-1-january-2021" data-track-options="{"dimension29":"Guidance for Great Britain (England, Wales and Scotland) Marketing Authorisation Applications for similar biological products (biosimilars) from 1 January 2021"}" href="#guidance-for-great-britain-england-wales-and-scotland-marketing-authorisation-applications-for-similar-biological-products-biosimilars-from-1-january-2021">Guidance for Great Britain (England, Wales and Scotland) Marketing Authorisation Applications for similar biological products (biosimilars) from 1 January 2021</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 2" data-track-label="#guidance-for-great-britain-marketing-authorisation-applications-for-advanced-therapy-medicinal-products-atmps-from-1-january-2021" data-track-options="{"dimension29":"Guidance for Great Britain Marketing Authorisation Applications for Advanced Therapy Medicinal Products (ATMPs) from 1 January 2021"}" href="#guidance-for-great-britain-marketing-authorisation-applications-for-advanced-therapy-medicinal-products-atmps-from-1-january-2021">Guidance for Great Britain Marketing Authorisation Applications for Advanced Therapy Medicinal Products (ATMPs) from 1 January 2021</a>

        </li>
        <li class="gem-c-contents-list__list-item gem-c-contents-list__list-item--dashed">
          <a class="gem-c-contents-list__link govuk-link " data-track-category="contentsClicked" data-track-action="content_item 3" data-track-label="#guidance-for-plasma-master-files-pmfs-and-vaccine-antigen-master-files-vamfs-from-1-january-2021" data-track-options="{"dimension29":"Guidance for Plasma Master Files (PMFs) and Vaccine Antigen Master Files (VAMFs) from 1 January 2021"}" href="#guidance-for-plasma-master-files-pmfs-and-vaccine-antigen-master-files-vamfs-from-1-january-2021">Guidance for Plasma Master Files (PMFs) and Vaccine Antigen Master Files (VAMFs) from 1 January 2021</a>

        </li>
    </ol>
</nav>
      </div>
    
      
<div class="gem-c-govspeak govuk-govspeak direction-ltr" data-module="govspeak">
      <div class="govspeak">
<h2 id="guidance-for-great-britain-england-wales-and-scotland-marketing-authorisation-applications-for-similar-biological-products-biosimilars-from-1-january-2021">Guidance for Great Britain (England, Wales and Scotland) Marketing Authorisation Applications for similar biological products (biosimilars) from 1 January 2021</h2>

<p>The guidance is written on the basis of Reg 53 of The Human Medicines Regulations 2012, as amended by the Human Medicines (Amendment etc.) (<abbr title="European Union">EU</abbr> Exit) Regulations 2019. It is our intention to update these Regulations to reflect the change of implementation dates following the Transition Period.</p>

<p>From 1 January 2021 the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> will regulate biosimilar products according to the same principles that are applicable now. Northern Ireland will follow the <abbr title="European Union">EU</abbr> acquis and <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> will regulate applications for bio similar from 1 January 2021 accordingly.</p>

<p>New applications to Great Britain will be assessed at national level and should be submitted using existing procedures for national applications.</p>

<p>For biosimilar applications submitted after 1 January 2021, the application can only be made with reference to a product that falls within the definition of reference medicinal products in regulation 48 of the Human Medicines Regulations 2012, as amended by the Human Medicines (Amendment etc.) (<abbr title="European Union">EU</abbr> Exit) Regulations 2019.</p>

<p>These will be products that have been authorised for at least 8 years. They can include products authorised in the UK and those authorised by conversion from <abbr title="European Union">EU</abbr> Marketing Authorisations (<abbr title="Marketing Authorisation">MA</abbr>). It also includes products for which an <abbr title="European Union">EU</abbr> marketing authorisation was in force on December 31st 2020 but which did not convert into Great Britain marketing authorisations as the holder opted out of that process, and products for which an <abbr title="European Union">EU</abbr> marketing authorisation has ceased to be in force for reasons not related to safety, quality or efficacy.</p>

<p>Data and market exclusivity period entitlements for reference medicinal products approved before the date of UK exit from the <abbr title="European Union">EU</abbr> will continue to be applicable in the UK.</p>

<p>As part of the supporting data package, Great Britain will continue to accept data generated on reference product sourced in accordance with the <a rel="external" href="https://www.ema.europa.eu/en/human-regulatory/research-development/scientific-guidelines/multidisciplinary/multidisciplinary-biosimilar" class="govuk-link">‘Guideline on similar biological medicinal products <abbr title="Committee for Medicinal Products for Human Use">CHMP</abbr>/437/04 Rev1’</a>.</p>

<p>We have <a href="https://www.gov.uk/drug-safety-update/biosimilar-products" class="govuk-link">more information about biosimilar products</a>.</p>

<h2 id="guidance-for-great-britain-marketing-authorisation-applications-for-advanced-therapy-medicinal-products-atmps-from-1-january-2021">Guidance for Great Britain Marketing Authorisation Applications for Advanced Therapy Medicinal Products (<abbr title="Advanced Therapy Medicinal Products">ATMPs</abbr>) from 1 January 2021</h2>

<p>From 1 January 2021, <abbr title="Advanced Therapy Medicinal Products">ATMPs</abbr> will be regulated nationally in relation to Great Britain by the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> according to the same principles that previously applied. In Northern Ireland <abbr title="Advanced Therapy Medicinal Products">ATMPs</abbr> will continue to be regulated according the <abbr title="European Medicines Agency">EMA</abbr>’s Centrally Authorised Procedure.</p>

<p>This means that marketing authorisation applications for <abbr title="Advanced Therapy Medicinal Products">ATMPs</abbr> will be assessed in accordance with the general provisions in place for the licensing of medicines, taking the specific requirements for this group of medicines into account.</p>

<p>Data, traceability, exemptions from licensing, packaging and post-authorisation requirements will remain unchanged from the current <abbr title="European Union">EU</abbr> requirements and will be transposed into UK law.</p>

<p>Definitions of individual classes of <abbr title="Advanced Therapy Medicinal Products">ATMPs</abbr> will remain unchanged and classification of <abbr title="Advanced Therapy Medicinal Products">ATMPs</abbr> in the UK will be undertaken by the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> <a rel="external" href="https://www.ema.europa.eu/en/documents/scientific-guideline/reflection-paper-classification-advanced-therapy-medicinal-products_en-0.pdf" class="govuk-link">in accordance with the legislation and current guidance</a>.</p>

<p>Accordingly, <abbr title="Advanced Therapy Medicinal Products">ATMPs</abbr> will continue to be classified into either:</p>

<ul>
  <li>gene therapy medicinal products</li>
  <li>somatic cell therapy medicinal products</li>
  <li>tissue engineered products</li>
</ul>

<h3 id="what-to-do-if-you-are-uncertain-about-classification">What to do if you are uncertain about classification</h3>

<p>If you are uncertain about the classification of your product fill out the <a rel="external" href="https://info.mhra.gov.uk/forms/atmp_form.aspx" class="govuk-link"><abbr title="Advanced Therapy Medicinal Product">ATMP</abbr> advice form</a> or consult the <a rel="external" href="https://www.ema.europa.eu/documents/scientific-guideline/reflection-paper-classification-advanced-therapy-medicinal-products_en-0.pdf" class="govuk-link">Reflection paper on classification of advanced therapy medicinal products (<abbr title="European Medicines Agency">EMA</abbr>/CAT/600280/2010 rev.1)</a>.</p>

<h2 id="guidance-for-plasma-master-files-pmfs-and-vaccine-antigen-master-files-vamfs-from-1-january-2021">Guidance for Plasma Master Files (<abbr title="Plasma Master Files">PMFs</abbr>) and Vaccine Antigen Master Files (<abbr title="Vaccine Antigen Master Files">VAMFs</abbr>) from 1 January 2021</h2>

<p>From 1 January 2021, the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> will continue to recognise the existing <abbr title="Plasma Master File">PMF</abbr> and associated inspections until further notice.</p>

<p>The supervision of the <abbr title="Plasma Master Files">PMFs</abbr> may eventually be fully transferred into a national system. This will be communicated by the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> at a later date. In the interim, we require the <abbr title="Plasma Master File">PMF</abbr> holder to notify the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> of the outcome of the annual updates within 4 weeks of the completion of the update.</p>

<p>For variation applications submitted to the <abbr title="European Medicines Agency">EMA</abbr>, the <abbr title="Plasma Master File">PMF</abbr> holder must notify the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> of the submission and determination outcome of such an application within 4 weeks of the submission and determination dates, respectively.</p>

<p><abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> reserve the right for further review where an <abbr title="European Union">EU</abbr> assessment report is deemed to indicate significant public health issues that are insufficiently addressed at European level.</p>

<p><abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> will issue guidance on the transfer of <abbr title="Plasma Master Files">PMFs</abbr> to the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> database when this becomes relevant, but the data requirements will be in accordance with those currently in place in the <abbr title="European Union">EU</abbr>.</p>

<p>No <abbr title="Vaccine Antigen Master File">VAMF</abbr> is in use in the UK at present. Applicants proposing such a submission, which will be subject to the same standards and criteria as apply now, should contact the <abbr title="Medicines and Healthcare products Regulatory Agency">MHRA</abbr> for further guidance.</p>

<p>This guidance will apply from 1 January 2021 in line with the <a rel="external" href="http://www.legislation.gov.uk/uksi/2019/775/contents/made" class="govuk-link">Human Medicines Regulations (Amendment etc.) (<abbr title="European Union">EU</abbr> Exit) Regulations 2019</a>.</p>

</div>
</div>


      <div class="responsive-bottom-margin">
        <div class="app-c-published-dates " lang="en">
    Published 1 September 2020
</div>

      </div>

      <div data-sticky-element class="app-c-contents-list-with-body__link-wrapper">
        <div class="app-c-contents-list-with-body__link-container">
          <a class="govuk-link app-c-back-to-top dont-print" href="#contents">
    <svg class="app-c-back-to-top__icon" xmlns="http://www.w3.org/2000/svg" width="13" height="17" viewbox="0 0 13 17">
      <path fill="currentColor" d="M6.5 0L0 6.5 1.4 8l4-4v12.7h2V4l4.3 4L13 6.4z"></path>
    </svg>
    Contents
</a>

        </div>
      </div>
  </div>
  </div>
  
<div class="govuk-grid-column-one-third">
  
<div class="gem-c-contextual-sidebar">
    <div class="gem-c-contextual-sidebar__brexit-cta govuk-!-margin-bottom-6" data-module="track-click">
  <h2 class="gem-c-contextual-sidebar__brexit-heading">Transition period</h2>
  <a href="/transition" class="govuk-link" data-track-category="relatedLinkClicked" data-track-action="1.0 Transition" data-track-label="/transition" data-track-options="{"dimension29":"Find out what it means for you"}">Find out what it means for you</a>
</div>



    
  <div class="gem-c-related-navigation">

      <h2 id="related-nav-related_items-5ef402b0" class="gem-c-related-navigation__main-heading" data-track-count="sidebarRelatedItemSection">
        Related content
      </h2>




      <nav role="navigation" class="gem-c-related-navigation__nav-section" aria-labelledby="related-nav-collections-5ef402b0" data-module="gem-toggle">

    <h3 id="related-nav-collections-5ef402b0" class="gem-c-related-navigation__sub-heading gem-c-related-navigation__sub-heading--sidebar" data-track-count="sidebarRelatedItemSection">Collection</h3>

  <ul class="gem-c-related-navigation__link-list" data-module="track-click">


        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--sidebar" data-track-category="relatedLinkClicked" data-track-action="1.1 Collection" data-track-label="/government/collections/mhra-post-transition-period-information" data-track-options="{"dimension28":"1","dimension29":"MHRA post-transition period information"}" href="/government/collections/mhra-post-transition-period-information">MHRA post-transition period information</a></li>

  </ul>
</nav>

  </div>



</div>

</div>

</div>


  <div class="govuk-grid-row">
    <div class="govuk-grid-column-two-thirds">
        
  <div class="gem-c-contextual-footer">
    
  <div class="gem-c-related-navigation">





      <nav role="navigation" class="gem-c-related-navigation__nav-section" aria-labelledby="related-nav-topics-5e4e8eca" data-module="gem-toggle">

    <h2 id="related-nav-topics-5e4e8eca" class="gem-c-related-navigation__sub-heading gem-c-related-navigation__sub-heading--footer" data-track-count="footerRelatedItemSection">Explore the topic</h2>

  <ul class="gem-c-related-navigation__link-list" data-module="track-click">


        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--footer" data-track-category="relatedLinkClicked" data-track-action="1.1 Explore the topic" data-track-label="/topic/medicines-medical-devices-blood/manufacturing-wholesaling-importing-exporting-medicines" data-track-options="{"dimension28":"2","dimension29":"Manufacturing, wholesaling, importing and exporting medicines"}" href="/topic/medicines-medical-devices-blood/manufacturing-wholesaling-importing-exporting-medicines">Manufacturing, wholesaling, importing and exporting medicines</a></li>
        <li class="gem-c-related-navigation__link"><a class="gem-c-related-navigation__section-link gem-c-related-navigation__section-link--footer" data-track-category="relatedLinkClicked" data-track-action="1.2 Explore the topic" data-track-label="/topic/medicines-medical-devices-blood/marketing-authorisations-variations-licensing" data-track-options="{"dimension28":"2","dimension29":"Marketing authorisations, variations and licensing guidance"}" href="/topic/medicines-medical-devices-blood/marketing-authorisations-variations-licensing">Marketing authorisations, variations and licensing guidance</a></li>

  </ul>
</nav>

  </div>

  </div>


    </div>
  </div>